

IMMUNOTECHNOLOGY CORP

Form 4

January 10, 2001

1

U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 4  
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person:  
Mark Scharmann, 1661 Lakeview Circle, Ogden, UT 84403
2. Issuer Name and Ticker or Trading Symbol:  
ImmunoTechnology Corp (IMNT.OB)
3. IRS or Social Security Number of Reporting Person (Voluntary):
4. Statement for Month/Year: 1/01
5. If Amendment, Date of Original (Month/Year):
6. Relationship of Reporting Person(s) to Issuer (Check all Applicable)  
(X) Director (X) Officer, give title below (X) 10% Owner ( ) Other  
Title: Secretary/Treasurer
7. Individual or Joint/Group Filing (Check Applicable Line)  
(X) Form filed by One Reporting Person  
( ) Form filed by More than One Reporting Person

TABLE I  
NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED

1. Title of Security: Common Stock
2. Transaction Date (Month/Day/Year): 11/21/2000
3. Transaction Code: J
4. Securities Acquired (A) or Disposed of (D): Amount: (A) 50,000
5. Amount of Securities Beneficially Owned at End of Month: 3,614,895
6. Ownership Form: Direct (D) or Indirect (I): (D) 3,478,045 (I) 136,850
7. Nature of Indirect Beneficial Ownership: 86,850 shares held by Troika Capital, LLC, an entity controlled by Mark Scharmann, and 50 shares held by the Mark A. Scharmann IRA

TABLE II  
DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF OR BENEFICIALLY OWNED

1. Title of Derivative Security:
2. Conversion or Exercise Price of Derivative Security:
3. Transaction Date (Month/Day/Year):
4. Transaction Code:
5. Number of Derivative Securities Acquired (A) or Disposed of (D):
6. Date Exercisable and Expiration Date (Month/Day/Year):
7. Title and Amount of Underlying Securities:
8. Price of Derivative Security:
9. Number of Derivative Securities Beneficially Owned at End of Month:
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I):
11. Nature of Indirect Beneficial Ownership:

Explanation of Responses:

Edgar Filing: IMMUNOTECHNOLOGY CORP - Form 4

Signature of Reporting Person: /S/Mark A. Scharmann  
Date: 1/8/01